Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®
(Thomson Reuters ONE) -
Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus(®) and
Lantus(®) SoloStar(®)
Paris, France - October 24, 2017 - Sanofi (EURONEXT: SAN and NYSE: SNY) today
filed a patent infringement suit against Mylan N.V., Mylan GmbH, Mylan Inc., and
Mylan Pharmaceuticals Inc. (collectively, "Mylan") in the United States District
Court for the District of New Jersey. Sanofi alleges infringement of 18 patents
in its suit.
The suit was triggered by notifications received from Mylan beginning in mid-
September, in which Mylan stated that it had filed a NDA (505(b)(2) New Drug
Application) with the FDA for insulin glargine pre-filled pen and vial drug
products. Mylan also stated that its NDA included a paragraph IV certification
challenging all of the Sanofi patents then listed in the FDA Orange Book for
Sanofi's Lantus(®) (insulin glargine injection, 100 Units/mL) and Lantus(®)
SoloStar(®) products.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are
a global biopharmaceutical company focused on human health. We prevent illness
with vaccines, provide innovative treatments to fight pain and ease suffering.
We stand by the few who suffer from rare diseases and the millions with long-
term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming
scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Contacts:
Media Relations Investor Relations
Ashleigh Koss George Grofik
Tel. : +1 (908) 981-8745 Tel.: +33 (0)1 53 77 45 45
Mobile: +1 (908) 205-2572 ir(at)sanofi.com
Ashleigh.Koss(at)sanofi.com
Press release (PDF):
http://hugin.info/152918/R/2143855/821493.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.10.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 565084
Anzahl Zeichen: 2470
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
